Adding to its growing roster of biomarker discovery collaborations, Ciphergen Biosystems said last week that it had embarked on a colon cancer biomarker study with infectious disease diagnostics company BioMérieux.
“The objective is to first discover markers and then develop them into products on our respective platforms,” said Robert Maurer, Ciphergen’s vice president of business development.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
